Carbapenem-resistant Gram-negative pathogens associated with septic shock: a review of 120 cases

References

• Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017;39:106–112.
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic resistance threats in the United States 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
   Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2019. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2019.pdf.
   Google Scholar
• Süzük Yıldız S, Şimşek H, Bakkaloğlu Z, et al. 2019 Yılı içinde izole edilen Escherichia coli ve Klebsiella pneumoniae izolatlarında karbapenemaz epidemiyolojisi [The epidemiology of carbapenemases in Escherichia coli and Klebsiella pneumoniae isolated in 2019 in Turkey]. Mikrobiyol Bul. 2021;55(1):1–16. [Türkiye’de]
   PubMedGoogle Scholar
• Bauer M, Gerlach H, Vogelmann T, et al. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019: results from a systematic review and meta-analysis. Crit Care. 2020;24(1):239.
   PubMed Web of Science ®Google Scholar
• Cag Y, Karabay O, Sipahi OR, et al. Development and validation of a modified quick SOFA scale for risk assessment in sepsis syndrome. PLoS One. 2018;13(9):e0204608.
   PubMed Web of Science ®Google Scholar
• Kurumu Tİ. Bölgesel İstatistikler (İzmir). Available from: https://biruni.tuik.gov.tr/bolgeselistatistik/tabloOlustur.do#.
   Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Setter NW, Peres ML, de Almeida BMM, et al. Charlson comorbidity index scores and in-hospital prognosis of patients with severe acute respiratory infections. Intern Med J. 2020;50(6):691–697.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl_2):S27–S72.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America. Clin Infect Dis. 2010;50(5):625–663.
   PubMed Web of Science ®Google Scholar
• Shah H, Bosch W, Thompson KM, et al. Intravascular catheter-related bloodstream infection. Neurohospitalist. 2013;3(3):144–151.
   PubMedGoogle Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. Available from: http://www.eucast.org.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Pop-Vicas A, Opal SM. The clinical impact of multidrug-resistant Gram-negative bacilli in the management of septic shock. Virulence. 2014;5(1):206–212.
   PubMed Web of Science ®Google Scholar
• Sipahi OR. Economics of antibiotic resistance. Expert Rev anti Infect Ther. 2008;6(4):523–539.
   PubMed Web of Science ®Google Scholar
• Arda B, Sipahi OR, Yamazhan T, et al. Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance. J Infect. 2007;55(1):41–48.
   PubMed Web of Science ®Google Scholar
• Gualtero S, Valderrama S, Valencia M, et al. Factors associated with mortality in infections caused by carbapenem-resistant enterobacteriaceae. J Infect Dev Ctries. 2020;14(06):654–659.
   PubMedGoogle Scholar
• Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, et al. Mortality of Pandrug-Resistant Klebsiella pneumoniae bloodstream infections in critically ill patients: a retrospective cohort of 115 episodes. Antibiotics (Basel). 2021;10(1):76.
   PubMed Web of Science ®Google Scholar
• Sabino S, Soares S, Ramos F, et al. A cohort study of the impact of Carbapenem-Resistant enterobacteriaceae infections on mortality of patients presenting with sepsis. mSphere. 2019;4(2):e00052–19.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22(5):444–450.
   PubMed Web of Science ®Google Scholar
• Oliva A, Bianchi A, Russo A, et al. Effect of N-Acetylcysteine administration on 30-Day mortality in critically ill patients with septic shock caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: a retrospective case-control study. Antibiotics (Basel). 2021;10(3):271.
   PubMed Web of Science ®Google Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063–e1143.
   PubMed Web of Science ®Google Scholar
• Serafim R, Gomes JA, Salluh J, et al. A comparison of the Quick-SOFA and systemic inflammatory response syndrome criteria for the diagnosis of sepsis and prediction of mortality: a systematic review and Meta-Analysis. Chest. 2018;153(3):646–655.
   PubMed Web of Science ®Google Scholar
• Li YY, Wang J, Wang R, et al. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):408.
   PubMed Web of Science ®Google Scholar
• Zak-Doron Y, Dishon Benattar Y, Pfeffer I, et al. The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant Gram-negative bacteria: a prospective study. Clin Infect Dis. 2018;67(12):1815–1823.
   PubMed Web of Science ®Google Scholar
• Balkhair A, Al-Muharrmi Z, Al’Adawi B, et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: description of a decade-long trend. Int J Infect Dis. 2019;85:10–15.
   PubMed Web of Science ®Google Scholar
• Boral B, Unaldi Ö, Ergin A, et al. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Ann Clin Microbiol Antimicrob. 2019;18(1):19.
   PubMedGoogle Scholar
• Acar A, Karaahmetoğlu G, Akalın H, et al. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis. J Glob Antimicrob Resist. 2019;18:64–70.
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Montravers P, Bassetti M. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018;31(6):587–593.
   PubMed Web of Science ®Google Scholar
• Bakır Ekinci P, Kurtaran M, Kara E, et al. Colistin-induced nephrotoxicity: Experience from a university hospital. Mediterr J Infect Microb Antimicrob. 2021;10:53.
   Web of Science ®Google Scholar
• Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71(2):304–310.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America guidance on the treatment of Extended-Spectrum β-lactamase producing enterobacterales (ESBL-E), Carbapenem-Resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183.
   PubMedGoogle Scholar
• Alataby H, Nfonoyim J, Diaz K, et al. The levels of lactate, troponin, and N-Terminal Pro-B-Type natriuretic peptide are predictors of mortality in patients with sepsis and septic shock: a retrospective cohort study. Med Sci Monit Basic Res. 2021;27:e927834.
   PubMed Web of Science ®Google Scholar
• Jouffroy R, Léguillier T, Gilbert B, et al. Pre-hospital lactatemia predicts 30-day mortality in patients with septic shock-preliminary results from the LAPHSUS study. JCM. 2020;9(10):3290.
   Google Scholar